Introduction
Pulmonary arterial hypertension (PAH) is a progressive and lethal disease characterized by pulmonary vascular remodeling. Recent studies have suggested that immunological abnormalities are associated with the vascular remodeling observed in PAH [1] [2] [3] [4] [5] . Regulatory T cells (Tregs) are a subpopulation of T cells, which play important roles in the maintenance of immune homeostasis and self-tolerance. These roles are performed by the secretion of anti-inflammatory cytokines such as interleukin (IL)-10 and transforming growth factor-β1 (TGF-β1), inhibition of effector T cell proliferation via the expression of cell surface molecule CD25, and contact with antigen-presenting cells through cell surface molecules such as cytotoxic T lymphocyte antigen 4 (CTLA-4), which reduces effector T cell activation [6, 7] . Tregs are generated in the thymus or are peripherally induced from CD4 + T cells mainly by TGF-β1 [6] . Impaired Tregs are implicated in the pathogenesis of PAH, presumably by failing to control inflammatory vascular cell injury [8] [9] [10] [11] , but the precise role of Tregs in PAH remains to be elucidated. Tregs are characterized by the expression of CD25 and intracellular Forkhead box protein 3 (FoxP3). Recent studies have revealed that CD4
+

FoxP3
+ Tregs are heterogeneous and can be characterized into three functionally and phenotypically different subsets by their expression levels of CD45RA, FoxP3, and CD25. Furthermore, alterations in Treg subsets are involved in various diseases and conditions [12] [13] [14] . Treg subsets include Abstract Regulatory T cells (Tregs) have been reported to play a pivotal role in the vascular remodeling of pulmonary arterial hypertension (PAH). Recent studies have revealed that Tregs are heterogeneous and can be characterized by three phenotypically and functionally different subsets. In this study, we investigated the roles of Treg subsets in the pathogenesis of PAH in eight patients with PAH and 14 healthy controls. Tregs and their subsets in peripheral blood samples were analyzed by flow cytometry. T cells was significantly higher in PAH patients than in controls (6.54 ± 1.10 vs. 3.81 ± 0.28 %, p < 0.05). Of the three subsets, the proportion of non-Tregs was significantly elevated in PAH patients compared with controls (4.06 ± 0.40 vs. 2.79 ± 0.14 %, p < 0.01), whereas those of rTregs and aTregs were not different between the two groups. Moreover, the expression levels of cytotoxic T lymphocyte antigen 4, a functional cell surface molecule, in aTregs (p < 0.05) and non-Tregs (p < 0.05) were significantly higher in PAH patients compared with controls. These results suggested the non-Treg subset was expanded and functionally activated in peripheral lymphocytes obtained from IPAH patients. We hypothesize that immunoreactions involving the specific activation of the 1 3 
low Tregs (non-Tregs) are CD25 high , have no suppressive activity, and produce pro-inflammatory cytokines such as IL-2 and interferon-gamma [12] . This study investigated whether phenotypically and functionally altered Treg subsets were present in PAH patients to define the precise role of Tregs in PAH pathogenesis.
Materials and methods
Study participants
This study included eight idiopathic PAH (IPAH) patients diagnosed by right heart catheterization (RHC) according to the following international standard criteria: mean pulmonary arterial pressure (PAP) of ≥25 mmHg with a pulmonary capillary wedge pressure of ≤15 mmHg and exclusion of secondary causes responsible for pulmonary hypertension. All patients had undergone RHC at least once for the first diagnosis of PAH or therapeutic evaluation in our hospital. None of the patients had received immunosuppressive treatments for at least 3 months. Patients with infections or malignant tumors were excluded from the analysis. Fourteen healthy volunteers were enrolled as a control group. The study was approved by the local ethics committee and carried out in accordance with the ethical guidelines of the 1975 Declaration of Helsinki. Written informed consent was obtained from each study participant.
Cell isolation and flow cytometric analysis
Blood samples were collected from each subject in heparin-treated tubes. Peripheral blood mononuclear cells (PBMCs) were separated immediately after blood sampling using Lymphoprep tubes (Axis-Shield PoC AS, Oslo, Norway) and density gradient centrifugation. For cell surface staining, PBMCs were resuspended in BD Pharmingen Stain Buffer (BD Bioscience, San Jose, CA, USA) and stained with the following fluorescently labeled anti-human antibodies: CD4-FITC, CD8-V500, CD25-APC, CD45RA-APCH7, and CD152 (CTLA-4)-Brilliant Violet 421 (BD Bioscience). Then the cells were stained for intracellular FoxP3 with an anti-human FoxP3-PE antibody (BD Bioscience). All samples were analyzed using a FACSAria II (BD Bioscience). The acquired data were processed by FlowJo version 7.6.5 Software (Tree Star Inc., Ashland, OR, USA).
RNA extraction and real-time polymerase chain reaction (PCR)
Total RNA was extracted from PBMCs using an RNeasy Mini Kit (Qiagen GmbH, Hilden, Germany). cDNA was synthesized from 100 ng total RNA by reverse transcription using a Transcriptor First Strand cDNA Synthesis Kit (Roche Diagnostic GmbH, Mannheim, Germany). Real-time PCR was performed on an ABI 7900HT Fast Real-Time PCR system (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions. The relative expression of target genes was quantified by the ΔΔCt method normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene expression. TaqMan Gene Expression Assays for human GAPDH, FoxP3, CTLA4, IL-10, and TGF-β1 were used as follows: GAPDH, Hs02758991_g1; FoxP3, Hs01085834_m1; CTLA-4, Hs03044418_m1; IL-10, Hs00961622_m1; TGF-β1, Hs00998133_m1 (Applied Biosystems). The results were analyzed using Expression Suite version 1.0 Software (Applied Biosystems).
Serum samples and cytometric bead array (CBA) analysis
Venous blood samples obtained from all participants were centrifuged after coagulation. Serum TGF-β1 concentrations were measured using a Human TGF-β1 Single Plex Flex Set (BD Bioscience) according to the manufacturer's instructions. Serum TGF-β1 concentrations were calculated using the mean fluorescence intensity (MFI) method. All samples were analyzed by FACSAria II. The acquired data were processed using FCAP Array version 3.0 Software (BD Bioscience).
Statistical analysis
Statistical analysis was performed with JMP version 10.0.2 software (SAS institute Inc., Cary, NC, USA). Data are presented as the mean ± standard error (SE). The nonparametric Mann-Whitney U test was used for comparative analysis between two groups. Linear regression analysis was performed for correlational analysis between two parameters. A two-tailed p value of <0.05 was considered statistically significant.
Results
Baseline characteristics
The clinical characteristics of participants are shown in Table 1 . The mean age of patients was 49.5 ± 9.6 years. At the time of diagnosis, the mean age was 47.4 ± 10.2 years old, and the mean PAP was 54 ± 6.4 mmHg. According to the functional classification of PAH by the World Health Organization, six patients (75 %) were categorized as class II and two patients (25 %) were categorized as class III. Five patients (62.5 %) were treated with prostanoids, and seven patients (87.5 %) were treated with a phosphodiesterase inhibitor. All patients were treated with an endothelin receptor antagonist. 
Flow cytometric analysis of Treg subsets
FoxP3
+ Tregs was significantly higher in the IPAH group than the control group (6.54 ± 1.10 vs. 3.81 ± 0.28 %, p < 0.05) (Fig. 2a) . Moreover, the proportion of CD4 +
CD45RA
− FoxP3 low non-Tregs was significantly higher in the IPAH group compared with the control group (4.06 ± 0.40 vs. 2.79 ± 0.14 %, p < 0.01) (Fig. 2d) . However, the proportions of CD4 (Fig. 2b, c) 
FoxP3
low rTregs were similar between groups (Fig. 3a) . There were no significant differences in cell surface expression levels of CD25 on each Treg subset between the IPAH and control groups (Fig. 3b) .
Gene expression analysis
Relative gene expression levels of FoxP3, CTLA-4, IL-10, and TGF-β1 evaluated in PBMCs obtained from each participant indicated no significant differences between IPAH and controls groups (Fig. 4) .
Cytokine analysis
Serum concentrations of TGF-β1 were lower in the IPAH group compared with the control group (4.41 ± 0.96 vs. 10.26 ± 1.11 ng/ml, p < 0.01) (Fig. 5) . However, there were no significant correlations between serum TGF-β1 concentrations and the proportions of Treg subsets in the IPAH group (data not shown).
Discussion
The present study revealed phenotypically and functionally altered Treg subsets in PAH patients. To the best of our knowledge, this is the first report to investigate the presence of Treg subsets in PAH patients. In a recent study, Tamosiuniene et al. [8] 
CD127
low Tregs expressing leptin receptor, considered to be dysfunctional Tregs, were increased in PAH patients. They also reported that serum leptin was higher in PAH patients than in controls, and isolated pulmonary endothelial cells (P-ECs) from IPAH patients produced more leptin. They concluded that increased leptin from P-ECs contributed to the immunopathogenesis of PAH through a functional decline of Tregs that was leptin-dependent. However, the precise mechanism has not been fully elucidated.
In this study, we demonstrated that the proportion of conventional CD4
FoxP3
+ Tregs was increased in IPAH patients compared to healthy controls. However, this finding does not simply indicate an increase in Treg activity, which suppresses the immune system. Subset analysis of Tregs 
high aTregs remained at the same levels. Because CD4 
low non-Tregs of IPAH patients. Given that CTLA-4 is highly upregulated after T 
low non-Tregs may be involved in the pathogenic mechanisms of PAH. To analyze the alterations in the phenotype and function of Treg subsets in more detail, relative gene expression levels in Tregs were compared between IPAH patients and controls. However, we did not observe significant differences in the expression levels of the analyzed genes. This might be due to study limitations including enrolling patients with various disease activities and treatments with therapeutic drugs. In addition, it would have been more appropriate to use purified total RNA from Treg subsets. However, insufficient amounts of total RNA were obtained from Treg subsets for real-time PCR analysis. Therefore, we used total RNA from PBMCs for the analyses. As Tregs are a minor population of total PBMCs, changes in Treg target gene expression levels were likely obscured by changes in the expression of other genes in major leukocyte populations. To the best of our knowledge, no previous studies have performed in vitro assays of Tregs from PAH patients. Therefore, to determine clearly the immunosuppressive property of Tregs in the disease, future studies should perform in vitro assays, and reliable protocols can be applied to human Tregs [16] . Nevertheless, our study suggests phenotypical and functional abnormalities in the Tregs of PAH patients might have a role in PAH pathogenesis.
Recent studies have demonstrated that TGF-β1 is key modulator in PAH pathogenesis, as well as Treg maintenance and proliferation [6] . The present study showed that the serum concentration of TGF-β1 was significantly lower in IPAH patients than in controls. Therefore, we hypothesized that the increase in the non-Treg subset was caused by the characteristic conditions of PAH. Mutations in the gene encoding bone morphogenetic protein (BMP) receptor-2 (BMPR2), a TGF-β1 receptor family member, are closely associated with the pathogenesis of PAH [17, 18] . In addition, mutations in activin receptor-like kinase (ALK) 1, also a member of the TGF-β1 receptor family, have been detected in some cases of PAH [19] . BMP and TGF-β1 control pulmonary cell proliferation through Smads and non-canonical pathways, such as the mitogen-activated protein kinase pathway [20] [21] [22] . BMP activates Smad1/5/8 via BMPR2, and TGF-β1 activates Smad2/3 via ALK5. Moreover, TGF-β1 activates Smad1/5/8 via BMPR2 and ALK1 complexes in vascular endothelial cells, and this BMP/TGF-β1 signaling contributes to pulmonary vascular homeostasis [23] . There is evidence that TGF-β1 and BMP exhibit growth-inhibitory effects on pulmonary artery smooth muscle cells (PASMCs) isolated from normal subjects [24] , and reduced functional BMPR2 expression in lung tissues are observed in PAH patients and experimental models of PAH [25] [26] [27] . Therefore, a decrease in circulating TGF-β1 might lead to impaired BMP/TGF-β1 signaling, resulting in the vascular remodeling of PAH. In contrast, Davies et al. [28] demonstrated that BMPR2 deficiency resulted in resistance to growth inhibition by TGF-β1 in human and murine PASMCs, in contrast to observed in normal PASMC responses. Additionally, treatment with hepatocyte growth factor overexpressing bone marrow mesenchymal stem cell transplantation in combination with granulocyte colony-stimulating factor administration attenuated the pulmonary vascular remodeling of an experimental PAH model accompanied by a reduction in serum TGF-β1 [29] , suggesting the BMP/TGF-β1 pathway has complicated and pleiotropic roles in the development of PAH. Furthermore, it still remains unresolved whether alterations in serum TGF-β1 levels occur as a cause or consequence of PAH. TGF-β1 also plays pivotal roles in the peripheral differentiation of Tregs from naïve CD4 + T cells and in the maintenance of thymus-derived Tregs [30] . Therefore, TGF-β1 was presumed to be associated with alterations in Treg subsets, but in the current study no significant correlation was observed between serum TGF-β1 concentrations and the proportions of Treg subsets. We speculate that TGF-β1, which is produced locally by numerous cell types such as endothelial cells, smooth muscle cells, fibroblasts, and blood cells in various organs including pulmonary vascular tissue, is important for the observed alterations in Treg subsets. In addition, other cytokines (IL-2, IL-4, and IL-6) involved in effector T cell differentiation of naïve CD4 + T cells that were reported to be elevated in PAH might contribute to alterations in the proportions of Treg subsets. Decreases in serum TGF-β1 concentrations may not contribute to alterations in Treg subsets, but rather to abnormal pulmonary vascular cell proliferation via an imbalance in the BMP/TGF-β1 signaling pathway. However, the precise mechanism underlying the alterations in Tregs remains to be elucidated.
In conclusion, an increased frequency of a functionally activated non-suppressive phenotype of Tregs is present in PAH patients, suggesting that an impaired immunosuppressive response contributes to vascular remodeling in PAH. These findings provide important information for the design of immunological studies of PAH and future therapeutic strategies.
